Bacterial species acting as biomarkers for obesity in domesticated cats and/or dogs are disclosed herein. Also disclosed are methods for diagnosing and/or treating cats and/or dogs having obesity or a predisposition to obesity as well as methods of screening for agents to treat or prevent obesity.

The present invention relates to methods and compositions for modifying mucous membranes. In particular, the present invention relates to treating diseases associated with mucous membranes by changing the intrinsic chemical composition and/or physical features of a target mucous membrane.

Methods of treating or preventing a vaginal infection of Gardnerella vaginalis in a subject involve administering to the subject an effective amount of a composition. The composition can include one or more of galactose, D-fucose, or mucin 5B. The composition can include one or more of galactose, N-acetyl D-galactosamine, N-acetyl D-glucosamine, D-fucose, or mucin 5B bonded to a surface, such as a polymer surface.

The present invention relates to methods and compositions for modifying mucous membranes. In particular, the present invention relates to treating diseases associated with mucous membranes by changing the intrinsic chemical composition and/or physical features of a target mucous membrane.

The present technology relates generally to formulations comprising egg white protein, methods of manufacturing egg protein formulations and uses for egg protein formulations. In particular, several embodiments are directed to egg protein formulations for oral administration in immunotherapy of subjects affected by egg allergies.

Disclosed herein is mucin-coated silica, compositions comprising the same, and methods of promoting the aggregation and/or clearance of oral bacteria using such compositions.

The present invention relates to a glycan composition useful as nutritional supplement, such as for instant formula supplement and as nutraceutical products and a method of preparation thereof.

Systems and methods are provided for generating and applying biomimicry tear film layers to a cornea surface. An example method includes forming a multiple layered tear film that are optically transparent, ultra-thin, and smoothly conforming to cornea surface. The multiple layered tear film can include a biomimicry adhesive layer, a biomimicry aqueous layer, and a biomimicry lipid layer. An atomizer/nebulizer/micronizer can be used to generate and applying the biomimicry tear film layers.

A therapeutic formulation containing mucin glycans derived from one or a number of nutritionally appropriate sources is described.

The present invention provides a biomarker PCDH9 for molecular classification of prostate cancer and for evaluation of prostate cancer prognosis and uses thereof. The biomarker PCDH9 can be DNA or mRNA of PCDH9 or a protein encoded thereby. The present invention also provides a prostate cancer in vitro diagnostic product comprising a detection reagent of the biomarker PCDH9.